Cargando…
A novel model for Ki67 assessment in breast cancer
ABSTRACT: BACKGROUND: Ki67 is currently the proliferation biomarker of choice, with both prognostic and predictive value in breast cancer. A lack of consensus regarding Ki67 use in pre-analytical, analytical and post-analytical practice may hinder its formal acceptance in the clinical setting. METHO...
Autores principales: | Romero, Quinci, Bendahl, Pär-Ola, Fernö, Mårten, Grabau, Dorthe, Borgquist, Signe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4069280/ https://www.ncbi.nlm.nih.gov/pubmed/24934660 http://dx.doi.org/10.1186/1746-1596-9-118 |
Ejemplares similares
-
Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies
por: Romero, Quinci, et al.
Publicado: (2011) -
Invasive lobular carcinoma of the breast: long-term prognostic value of Ki67 and histological grade, alone and in combination with estrogen receptor
por: Narbe, Ulrik, et al.
Publicado: (2014) -
The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naïve women with N0/N1 primary breast cancer
por: Strand, Carina, et al.
Publicado: (2013) -
High CYP27A1 expression is a biomarker of favorable prognosis in premenopausal patients with estrogen receptor positive primary breast cancer
por: Inasu, Maria, et al.
Publicado: (2021) -
The Prognostic Value of Mitotic Activity Index (MAI), Phosphohistone H3 (PPH3), Cyclin B1, Cyclin A, and Ki67, Alone and in Combinations, in Node-Negative Premenopausal Breast Cancer
por: Klintman, Marie, et al.
Publicado: (2013)